Table 4. Outcomes for early-relapsing... | American Society of Hematology

Table 4.

Outcomes for early-relapsing patients with T-cell-directed therapies

Drug	ORR (overall)	ORR (POD24)	CR (Overall)	CR (POD24)	PFS (Overall)	PFS (POD24)	OS
Axi-cel⁴⁴	94%	92%	79%	N/A	64.8% at 18 mo	55.3% at 18 mo	87.4% at 18 mo
Tisa-cel⁴⁵	86.2%	N/A	69.1%	59%	67% at 12 mo	N/A	N/A
Mosunetuzumab⁴⁹	78.9%	83%	57.8%	55%	17.9 mo median	N/A	N/A
Mosun + Len⁵⁰	92%	N/A	77%	N/A	N/A	N/A	N/A
Glofitamab⁴⁸	81%	N/A	70%	58%	N/A	N/A	N/A
Glofit + O⁴⁸	100%	N/A	73.7%	70%	N/A	N/A	N/A
Epcoritamab⁴⁷	90%	N/A	50%		N/A	N/A	N/A

Drug	ORR (overall)	ORR (POD24)	CR (Overall)	CR (POD24)	PFS (Overall)	PFS (POD24)	OS
Axi-cel⁴⁴	94%	92%	79%	N/A	64.8% at 18 mo	55.3% at 18 mo	87.4% at 18 mo
Tisa-cel⁴⁵	86.2%	N/A	69.1%	59%	67% at 12 mo	N/A	N/A
Mosunetuzumab⁴⁹	78.9%	83%	57.8%	55%	17.9 mo median	N/A	N/A
Mosun + Len⁵⁰	92%	N/A	77%	N/A	N/A	N/A	N/A
Glofitamab⁴⁸	81%	N/A	70%	58%	N/A	N/A	N/A
Glofit + O⁴⁸	100%	N/A	73.7%	70%	N/A	N/A	N/A
Epcoritamab⁴⁷	90%	N/A	50%		N/A	N/A	N/A

Len, lenalidomide; N/A, not available; O, observation.